Bausch Health Companies Inc. (NYSE:BHC) is set to announce third quarter earning results on Tuesday 3rd November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BHC to report 3Q20 income of $ 1.04 per share.
For the full year, analysts anticipate top line of $ 7887.71 million, while looking forward to income of $ 3.64 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 2,100.00 million ~ $ 2,100.00 million
Full Year 2020 topline are forecasted in a range of$ 7,800.00 million ~ $ 8,000.00 million
Click Here For More Historical Outlooks Of Bausch Health Companies Inc.
Previous Quarter Performance
Bausch Health Companies Inc. posted income for the second quarter of $ 0.46 per share, from the revenue of $ 1,664.00 million. The quarterly earnings 57.01 percent while revenues down 22.68 percent compared with the same quarter last year.
According to street consensus, BHC was expected to report 2Q20 income of $ 0.66 per share from revenue of $ 1794.83 million. The bottom line results missed street analysts by $ 0.2 or 30.3 percent, at the same time, top line results fell short of analysts by $ 130.83 million or 7.29 percent.
Stock Performance
Shares of Bausch Health Companies Inc. traded up $ 0.86 or 5.21 percent on Monday, reaching $ 17.36 with volume of 4.86 million shares. Bausch Health Companies Inc. has traded high as $ 17.36 and has cracked $ 16.51 on the downward trend
The closing price of $ 17.36, representing a 47.98 % increase from the 52 week low of $ 11.15 and a 48.39 % decrease over the 52 week high of $ 31.97.
The company has a market capital of $ 6.16 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Recent Analyst recommendations
- On 17th September 2020, upgraded by Bank of America to Neutral from Underperform rating, with $ 19.00 target price.
Conference Call
Bausch Health Companies Inc. will be hosting a conference call at 8:00 AM eastern time on 3rd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.bauschhealth.com
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
